Why Aren’t Biosimilars Delivering the Savings We Hoped For? Given the high cost of biologic drugs when the first biosimilars began to be developed, expectations for their cost-saving potential were high. Unfortunately, in the near decade since the first biosimilar was approved of filgrastim-sndz (Zarxio; Sandoz) in 2015, this promise has failed to materialize. Read more about the challenges biosimilars face and what needs to change. https://lnkd.in/ew9jsRQS
The Center for Biosimilars
Book and Periodical Publishing
Cranbury, NJ 16,294 followers
The authoritative resource for emerging therapies.
About us
Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.
- Website
-
http://www.centerforbiosimilars.com
External link for The Center for Biosimilars
- Industry
- Book and Periodical Publishing
- Company size
- 2-10 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
- Founded
- 2016
- Specialties
- biosimilars, biosimilar news, pharmaceuticals, policy, regulatory, and clinical
Locations
-
Primary
-
Cranbury, NJ 08512, US
Employees at The Center for Biosimilars
Updates
-
Biosimilar Policy Roundup for September 2024! 2024 has been a significant year for biosimilars! Key Highlights: * Cost Savings * Expanded Access * Regulatory Challenges * Future Outlook What are your thoughts on the role of biosimilars in health care? https://lnkd.in/ehtuSQ3c
-
New Option for Autoimmune Conditions? The FDA just approved a new treatment option for Crohn disease, ulcerative colitis, psoriasis, and psoriatic arthritis! It's called Otulfi, and it's a biosimilar to Stelara. Is Otulfi right for you? Click the link to learn more about biosimilars and see if this new option might be a good fit for you and your doctor to discuss. https://lnkd.in/gF6PqTDG
-
FTC Strikes Back Against Big Pharma! 💊 Days after Express Scripts sued the FTC over a critical report, the FTC is firing back with a lawsuit against the 3 largest PBMs. The FTC accuses these companies of manipulating insulin prices to line their pockets, leaving patients footing the bill. Is this a major victory for consumers? Read on to find out! https://lnkd.in/edf5Ckwc
-
Ivo Abraham, PhD, RN, from the University of Arizona Cancer Center, discusses trends, challenges, and opportunities of biosimilars. Abraham emphasizes the hesitancy some have toward biologic drugs, believing they may not be as effective as the originators. He also highlights price erosion and potential drug shortages affecting future accessibility. Click the link to watch the full video! https://lnkd.in/emCyBrCG
-
Dr. Vibeke Strand, a leading expert in immunology/rheumatology, shares insights from the VOLTAIRE-RA trial on patient-reported outcomes. To learn more about the latest in rheumatoid arthritis research, click the link below https://lnkd.in/efQ3Evey
-
The top 5 biosimilar news stories of the week include: *High patient satisfaction with biosimilars for IBD! *Effective & affordable treatment for HER2-positive breast cancer! *Is it time for biosimilars to be as affordable as generics? *Biosimilars saving a staggering $445 billion in 2023! *Fifth Eylea biosimilar approved in the US! Click the link below to watch the full video! https://lnkd.in/etfUFR-D
-
ICYMI: This two-part series displays savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the AAM! Check out both parts to learn more about savings by drug type, plan type, treatment space, and state, as well as drug shortages and market sustainability! https://lnkd.in/e67Y7fcB https://lnkd.in/eVB7HffZ
-
The European Commission has approved Celltrion's new biosimilar, SteQeyma, offering a more affordable treatment option. Plus, Celltrion has partnered with Cigna and Express Scripts to expand access to Zymfentra! This is a major step towards improving health care affordability and accessibility! https://lnkd.in/e2J8DNFJ
-
IRA's Boost to Oncology Biosimilars: A Small Step Forward The IRA aimed to increase the use of cost-saving biosimilars in oncology treatment. While it has had some positive impact, its influence has been limited by existing market competition. Read our latest article to find out how the IRA has impacted the availability and affordability of cancer treatments. https://lnkd.in/eG2yaeUH